文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.

作者信息

Rasmussen Line Jee Hartmann, Ladelund Steen, Haupt Thomas Huneck, Ellekilde Gertrude, Poulsen Jørgen Hjelm, Iversen Kasper, Eugen-Olsen Jesper, Andersen Ove

机构信息

Clinical Research Centre, Copenhagen University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark.

Acute Medical Department, Copenhagen University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark.

出版信息

Emerg Med J. 2016 Nov;33(11):769-775. doi: 10.1136/emermed-2015-205444. Epub 2016 Sep 2.


DOI:10.1136/emermed-2015-205444
PMID:27590986
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5136705/
Abstract

OBJECTIVE: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker associated with presence and progression of disease and with increased risk of mortality. We aimed to evaluate the unspecific biomarker suPAR as a prognostic marker in patients admitted to acute care. METHODS: This registry-based retrospective cohort study included 4343 consecutively admitted patients from the Acute Medical Unit at a large Danish university hospital. Time to readmission and death were analysed by multiple Cox regression. Results were reported as HRs for 30-day and 90-day follow-up. RESULTS: During 30-day follow-up, 782 patients (18.0%) were readmitted and 224 patients (5.2%) died. Comparing 30-day readmission and mortality between patients in the highest and lowest suPAR quartiles yielded HRs of 2.11 (95% CI 1.70 to 2.62) and 4.11 (95% CI 2.46 to 6.85), respectively, when adjusting for age, sex, Charlson score and C reactive protein. Area under the curve for receiver operating characteristics curve analysis of suPAR for 30-day mortality was 0.84 (95% CI 0.81 to 0.86). Furthermore, in the entire cohort, women had slightly higher suPAR compared with men, and suPAR was associated with age, admission time, admission to intensive care unit and Charlson score. CONCLUSIONS: In this large unselected population of acute medical patients, suPAR is strongly associated with disease severity, readmission and mortality after adjusting for all other risk factors, indicating that suPAR adds information to established prognostic indicators. While patients with low suPAR levels have low risk of readmission and mortality, patients with high suPAR levels have a high risk of adverse events.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baac/5136705/549c93bbab41/emermed-2015-205444f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baac/5136705/7e2770ae8270/emermed-2015-205444f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baac/5136705/549c93bbab41/emermed-2015-205444f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baac/5136705/7e2770ae8270/emermed-2015-205444f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baac/5136705/549c93bbab41/emermed-2015-205444f02.jpg

相似文献

[1]
Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.

Emerg Med J. 2016-11

[2]
suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients.

Scand J Trauma Resusc Emerg Med. 2018-2-1

[3]
Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.

Crit Care Med. 2018-12

[4]
Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study.

Crit Care. 2012-7-23

[5]
The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma - a retrospective cohort study.

Respir Res. 2019-11-15

[6]
Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.

Respir Res. 2018-5-21

[7]
suPAR as a biomarker for risk of readmission and mortality in the acute medical setting.

Dan Med J. 2015-10

[8]
The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.

Resuscitation. 2014-11

[9]
High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD.

Int J Chron Obstruct Pulmon Dis. 2020

[10]
Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.

Indian J Pediatr. 2016-7

引用本文的文献

[1]
The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP).

Clin Respir J. 2025-6

[2]
Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation.

J Arrhythm. 2025-4-23

[3]
Soluble Urokinase Plasminogen Activator Receptor: A Useful Marker for Predicting Mortality in COVID-19 Patients.

Cureus. 2024-11-25

[4]
SEPSIGN: early identification of sepsis signs in emergency department.

Intern Emerg Med. 2024-10-30

[5]
Examining the association between prenatal and perinatal adversity and the psychotic experiences in childhood.

Psychol Med. 2024-7

[6]
Social isolation, loneliness, and inflammation: A multi-cohort investigation in early and mid-adulthood.

Brain Behav Immun. 2024-1

[7]
Soluble Urokinase-Type Plasminogen Activator Receptor in Comatose Survivors After Out-of-Hospital Cardiac Arrest Treated with Targeted Temperature Management.

Ther Hypothermia Temp Manag. 2024-12

[8]
SuPAR in major depression: Association with 26 weeks antidepressant response and 10-year depression outcomes.

Brain Behav Immun Health. 2023-9-7

[9]
The predictive value of modified soluble urokinase plasminogen activator receptor (suPAR) with National Early Warning Score (NEWS) for mortality in emergency elderly patients in Japan: a prospective pilot study.

Acute Med Surg. 2023-5-30

[10]
Early Life Stress, Neuroinflammation, and Psychiatric Illness of Adulthood.

Adv Exp Med Biol. 2023

本文引用的文献

[1]
Soluble Urokinase Receptor and Chronic Kidney Disease.

N Engl J Med. 2015-11-12

[2]
suPAR as a biomarker for risk of readmission and mortality in the acute medical setting.

Dan Med J. 2015-10

[3]
Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.

HIV Med. 2016-5

[4]
suPAR: A New Biomarker for Cardiovascular Disease?

Can J Cardiol. 2015-10

[5]
Prolonged patients' In-Hospital Waiting Period after discharge eligibility is associated with increased risk of infection, morbidity and mortality: a retrospective cohort analysis.

BMC Health Serv Res. 2015-6-25

[6]
Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.

Biomark Insights. 2014-12-16

[7]
High levels of bed occupancy associated with increased inpatient and thirty-day hospital mortality in Denmark.

Health Aff (Millwood). 2014-7

[8]
Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.

Kidney Int. 2014-6-4

[9]
Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.

J Clin Lab Anal. 2012-1

[10]
Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.

J Intern Med. 2014-4-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索